Ann: Notification regarding unquoted securities - CGS, page-35

UK, Yes this is an interesting one but I would suggest it is more likely to be a possibility rather than a probability. I think it will ultimately depend on the trial design and if they want to harmonise it with the Phase III or not. If they do want to harmonise it, they will use the same assessment methodology and we know that was not provided by Cogstate and was not digital. If they go for a new digital assessment they really only have a choice between Cogstate and Cambridge Cognition. As you may be aware Biogen seems to have broken towards Cambridge Cognition (providing their marketing tool and rumored to be providing the cognition tools for their Biogen/Apple Intuition study in to MCI) but obviously Eisai has broken for us, so there are some reasons to be hopeful. But your right it is going to be a very significant contract for someone.